Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic and preclinical data with limited human trial evidence
PubMed 42653808 · doi:10.3390/ph19081313
What was done
A structured narrative review prepared according to SANRA quality criteria evaluated the mechanistic basis and clinical evidence for berberine-mediated supplement-drug interactions. Searches were conducted across PubMed/MEDLINE, Scopus, Web of Science, and Embase through May 2026. The authors synthesized interaction pathways across four mechanistic axes and proposed a three-tier risk-stratification framework linking perpetrator potency, victim-drug vulnerability, and patient risk to clinical pharmacy actions.
What was found
Berberine has low systemic oral bioavailability (0.68% in rats; low ng/mL plasma concentrations in humans) but achieves high luminal, enterocytic, and hepatic concentrations. Identified interaction mechanisms include CYP enzyme modulation (CYP3A4 inhibition and induction; quasi-irreversible CYP2D6 and CYP2C9 inhibition via metabolite-intermediate complexes), transporter modulation (P-glycoprotein, OCT1/OCT2, and MATE1), pharmacodynamic additivity (hypoglycemia, hypotension, QT prolongation), and potential microbiome/gut-barrier effects. In clinical human data, berberine co-administration in renal-transplant recipients increased cyclosporine area under the curve (AUC) by 34.5% and trough concentrations by 29.3% relative to control.
Why it matters
Berberine is widely used for metabolic self-medication but acts as an active pharmacological perpetrator capable of altering the safety and efficacy of co-administered prescription drugs, particularly those with narrow therapeutic indices. Clinicians must routinely reconcile berberine use and apply mechanistic risk stratification to prevent adverse drug interactions.
Limits
As a narrative review, the synthesis does not follow systematic review methodology or formal meta-analytic pooling, and the total number of included studies is not reported. Most documented interactions are mechanistic or preclinical, with only a small number of drug pairs validated in human trials. Unstandardized product quality and differing regulatory dosage limits also introduce significant variability into actual patient exposure.
Cited by
- supports Less than 1% of standard oral berberine and curcumin is absorbed across the intestinal barrier.